National University Cancer Institute, Singapore

What National University Cancer Institute, Singapore does

National University Cancer Institute, Singapore (NCIS) is a public-sector cancer centre and one of two designated national specialist centres for cancer in Singapore, operating within the National University Health System (NUHS) on the National University Hospital (NUH) campus. It delivers multidisciplinary cancer care across medical, surgical, radiation, and haematology oncology, plus specialty services spanning cancer genetics, geriatric oncology, ophthalmic oncology, paediatric haematology-oncology, palliative medicine, psychosocial oncology, and oncology pharmacy. NCIS runs specialised treatment programmes including CAR-T cell therapy, haematopoietic stem cell transplantation, proton beam therapy, HIPEC and PIPAC for peritoneal disease, histotripsy (via the HALT trial), scalp cooling, and the Haematology-Oncology Research Group (HORG) research arm focused on cancers endemic to Asia. Community-facing delivery is supported by the NCIS Home Care Programme, NCIS On The Go (NOTG) mobile outreach, TeleConsult virtual visits, and blood-taking at polyclinics, with survivorship, rehabilitation, and multiple patient support groups (Multiple Myeloma, NPC oneHeart, Sarcoma, Walnut Warriors).

The business model is that of a Singapore public healthcare institution: fees are regulated by the Ministry of Health (MOH), with MOH Fee Benchmarks applied across chemotherapy and related services, supplemented by philanthropic funding through the NCIS Cancer Fund (a sub-fund of the NUHS Fund) that covers approximately 80 financially disadvantaged patients per year. Strategic research funding comes from major philanthropic partners including the Li Ka Shing Foundation and Temasek Trust, which co-fund the $12 million HALT histotripsy trial. Patient acquisition is driven by referrals through NUHS polyclinics and primary care, self-referral, and a dedicated international patient channel, with marketing conducted through social media, awareness month campaigns, peer-reviewed publications, and events such as Relay for Life, NCAM, ISOS, and SkinCAM. NCIS integrates with Singapore's National Electronic Health Record (NEHR) and operates under PDPA and Private Hospitals and Medical Clinics Act compliance.

Recent strategic activity is concentrated in research-driven product and capability expansion: launch of NUGEM genomic medicine (April 2026), continued HALT histotripsy trial enrolment (10 patients as of June 2026), publication of the LARA trial in The Lancet Oncology, co-publication of the sarcoma clinical management handbook (April 2026), and active knowledge export across Asia via IASO MIDCON 2026. Awards include MASCC Centre of Excellence, Singapore Health Quality Service Award 2026, and Nurses' Merit Award 2025, supporting a strong clinical reputation rather than a commercial growth narrative.

Name

National University Cancer Institute, Singapore

Legal name

National University Cancer Institute, Singapore (NCIS)

Website

https://ncis.com.sg

Company type

Private

Founded year

1988

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

NCIS is a Singapore public-sector cancer centre and one of two national specialist centres for cancer, providing multidisciplinary oncology care, advanced therapies (CAR-T, proton beam, histotripsy), clinical research, and community programmes within the NUHS ecosystem.

Ownership category

akta.pro rank

Product category

Oncology Care Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Offices of Physicians (62111), Medical and Diagnostic Laboratories (62151)

SIC

Services-General Medical & Surgical Hospitals, Nec (8062), Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM)

akta.pro secondary industries

Medical Oncology (HLAKAFAB), Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI), Chronic Disease & NCD Program Evaluation (e.g., diabetes/CVD/cancer) (HLAJANAG), Public Research Universities with Academic Medical Centers (AMCs) (EDAHAAAC), Healthcare Clinical Professions (CME/CE for Nurses, Allied Health, Pharmacy) (EDAAALAC)

Keywords

• Oncology care services
• Cancer treatment
• Radiation oncology
• Clinical research
• Surgical oncology

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Distribution channels7 records

Marketing channels12 records

Core offering

NCIS is a public, non-profit cancer institute providing multidisciplinary, integrated oncology care across medical, surgical, radiation, haematology, cellular therapy, and supportive care disciplines. It delivers specialty oncology services (including cancer genetics, paediatric haem-oncology, and palliative care), advanced treatments such as CAR-T, stem cell transplant, proton beam therapy, HIPEC, and PIPAC, alongside clinical research, education, and community/home care programmes. The institute operates as one of two national specialist centres for cancer in Singapore within the NUHS academic health system.

Product overview

The National University Cancer Institute, Singapore (NCIS) is a comprehensive cancer centre providing integrated oncology services as part of the National University Health System (NUHS). The institution offers a full spectrum of cancer care through multiple specialty services including Medical Oncology, Haematology, Radiation Oncology, Surgical Oncology, and specialized programmes such as CAR-T Cell Therapy, Haematopoietic Stem Cell Transplant, and Proton Beam Therapy. NCIS provides care across the cancer journey from diagnosis through treatment, survivorship support, and end-of-life care. The institution operates community-based services through its Home Care Programme and On The Go Programme, while the Haematology-Oncology Research Group (HORG) drives clinical research and trials. Financial support is available through the NCIS Cancer Fund for approximately 80 financially disadvantaged patients annually. The institute publishes the annual SPARK by NCIS and Inside NCIS newsletter, and has developed clinical guidance including the sarcoma management handbook.

Differentiator

Problem solved

Functional benefit

Brands

• Haematology-Oncology Research Group (HORG): The research arm of NCIS comprising haematologists and oncologists committed to research of cancers endemic to Asia, with a special interest in development of novel drugs for cancer treatment
• NCIS Cancer Fund
• NCIS Dream Makers
• NCIS On The Go Programme (NOTG)
• NCIS Home Care Programme

Products and services

• Cancer Genetics Clinics

Quantifiable outcome

• 40% confirmed tumour response rate within 24 weeks in recurrent clear cell ovarian and endometrial cancers (LARA trial, 25 patients)
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature14 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• National Cancer Centre Singapore (NCCS) - Sarcoma CollaborationcoreStrategic or Co-development Partner · 11 April 2026NCIS and NCCS clinicians jointly developed expert multidisciplinary guidance including the 'Clinical Management of Bone and Soft Tissue Tumours' handbook, with 70 local and international contributors across orthopaedic oncology, pathology, radiology, surgery, medical oncology, and allied health.
• International Sarcoma ContributorsminorStrategic or Co-development Partner · 11 April 202670 local and international contributors across multiple specialties collaborated to develop the 'Clinical Management of Bone and Soft Tissue Tumours' handbook, supporting healthcare professionals in navigating complex diagnostic pathways and specialist referral identification for sarcoma.
• National University Health System (NUHS) - NUGEM LaunchcoreStrategic or Co-development Partner · 2 April 2026NUHS launched the National University Centre for Genomic Medicine (NUGEM) at its Scientific and Innovation Summit 2026, officiated by Mr Heng Swee Keat, Chairman of the National Research Foundation. NUGEM integrates genomic medicine across NUHS hospitals including NUH and the Yong Loo Lin School of Medicine at NUS.
• Singapore General Hospital (SGH)coreStrategic or Co-development Partner · 19 March 2026Singapore General Hospital is a co-site for the HALT histotripsy liver cancer trial, alongside National Cancer Centre Singapore. The collaboration enables cross-institutional clinical research on non-invasive ultrasound treatment.
• National Cancer Centre Singapore (NCCS)coreStrategic or Co-development Partner · 19 March 2026National Cancer Centre Singapore is a co-site for the HALT histotripsy liver cancer trial. NCIS clinicians collaborate with NCCS on this trial as well as on sarcoma care guidance and multidisciplinary tumour management.
• Relay For Life SingaporeminorOthers · 14 March 2026NCIS participates in Relay For Life at the National Stadium, an overnight cancer awareness and fundraising movement. Team NCIS fielded 128 runners in 2026, raising $13,160 and covering 165.2km over 12 hours.
• Indian Association of Surgical Oncology (IASO)minorStrategic or Co-development Partner · 7 February 2026International experts from NCIS and South Korea presented at IASO MIDCON 2026 in Raipur, India, sharing knowledge on advanced surgical oncology techniques including machine learning applications and robotic surgery comparisons (COLRAR Trial).
• NUHS FundcoreStrategic or Co-development Partner · 28 January 2026The NCIS Cancer Fund is a sub-fund of the NUHS Fund, providing financial assistance to approximately 80 financially disadvantaged cancer patients per year to support treatment initiation, continuity of care, and medical follow-ups.
• Singapore Cancer Society (SCS)minorStrategic or Co-development Partner · 28 January 2026NCIS patient ambassadors and support group members (Walnut Warriors Prostate Cancer Support Group, Multiple Myeloma Support Group, NPC oneHeart Support Group, Sarcoma Support Group) are active with the Singapore Cancer Society, participating in awareness programmes, educational talks, and community activities.
• International LARA Trial Sites (Singapore and South Korea)coreStrategic or Co-development Partner · 1 January 2021The LARA trial is an international multicentre Phase 2 study led by NCIS and conducted across Singapore and South Korea between 2021 and 2023, investigating dual-pathway blockade therapy for recurrent clear cell ovarian and endometrial cancers.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• OncoCare Cancer Centre: A private medical oncology practice in Singapore focused on cancer diagnosis and systemic therapy. It operates as a specialist competitor within the same city as NCIS, attracting patients seeking outpatient chemotherapy and second-opinion consultations outside the public system.
• Parkway Cancer Centre: Private-sector oncology provider within IHH Healthcare's Mount Elizabeth / Gleneagles network in Singapore. It offers medical and radiation oncology to paying and international patients, competing with NCIS for high-margin and medical-tourism cases while overlapping on clinical services.

Regional players

• Tan Tock Seng Hospital (TTSH): Another large Singapore public hospital within the National Healthcare Group offering medical and surgical oncology services. TTSH serves an overlapping domestic patient base and is a comparable public-sector peer for general oncology service delivery, though not a national cancer-designated centre like NCIS.
• KK Women's and Children's Hospital (KKH): A major public hospital in Singapore operating paediatric haematology-oncology and women's cancer services. It is a regional comparator within Singapore for paediatric oncology (NCIS also runs paediatric haem-onc) and gynaecologic cancers, where NCIS's LARA trial focuses.

Broad incumbents

• Peter MacCallum Cancer Centre: Australia's largest dedicated cancer hospital, integrated with the University of Melbourne. It shares NCIS's profile as a comprehensive public-sector cancer centre operating advanced therapies (including cellular therapy), clinical trials, and translational research across an Asia-Pacific population base.
• MD Anderson Cancer Center: Global benchmark comprehensive cancer centre within the University of Texas system. Comparable to NCIS in offering full multidisciplinary oncology, advanced therapies, and translational research, but operating at much larger scale and as a long-tail benchmark for NCIS's research and clinical-trial ambitions.

Direct peers

• National Cancer Center Japan: Japan's national cancer hospital and research institute under the Ministry of Health. It is a national-designation counterpart in an East-Asian public health system, operating multidisciplinary oncology care, advanced therapies, and a research portfolio with population-specific focus.
• National Cancer Centre Singapore (NCCS): Singapore's other national specialist cancer centre and NCIS's principal counterpart. Both deliver multidisciplinary oncology, run joint clinical trials (HALT histotripsy), and co-produce the sarcoma clinical management handbook, making them direct, head-to-head peers within the same national public oncology ecosystem.
• Singapore General Hospital (SGH) - Oncology: Major public hospital in Singapore operating across multiple medical specialties including oncology. It is a co-site for the HALT histotripsy trial and shares Singapore's National Electronic Health Record (NEHR) with NCIS, making it a direct comparable for inpatient oncology services and a partner-competitor for cancer referrals.
• Seoul National University Cancer Hospital: South Korea's leading academic cancer hospital, collaborating with NCIS on the LARA Phase 2 trial and sharing an Asian-population research focus. It is a comparable Asian academic cancer centre with advanced therapies, clinical trials, and an integrated research arm.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/user/NCISNUHS
• Facebookfacebook.com/NationalUniversityCancerInstituteSingapore
• LinkedInlinkedin.com/company/national-university-cancer-institute-singapore
• Instagraminstagram.com/ncis.nuhs

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about National University Cancer Institute, Singapore